Pharmaceutical Excipients Market - Forecast 2021 to 2026

The global pharmaceutical excipients market is projected to witness a CAGR of 7.31% during the forecast period to reach a total market size of US$9.776 billion by 2026, increasing from US$5.966 billion in 2019.

Introduction

Excipients are pharmacologically inactive chemicals that are added to the active drug substance to help with lubricity, flowability, disintegration, taste, and may provide some type of antibacterial action, as well as helping physiological absorption of the medication. Some of the excipients used in pharmaceutical industries include fillers, binders, lubricants, flavouring agents, sweeteners, chelating agents, solvents, co-solvents, etc.

Market Drivers

Tablets, capsules, oral liquids, topical creams and gels, implants, eye products, injectable products, inhalers, transdermal patches, and suppositories are a few of the dose forms available. Pharmaceutical excipients are used in pharmaceutical dosage forms to help the production process, protect, support, or increase stability.

Cancer, chronic lung disease, stroke, diabetes, and other chronic illnesses are today's leading causes of mortality and disability. In the United States alone, six out of ten individuals suffer from a chronic illness, needing frequent medication. According to the International Diabetes Federation (IDF), around 463 million individuals (20-79 years) had diabetes in 2019, with this number expected to climb to 700 million by 2045. Indicating a high demand for medication and thus Pharmaceutical Excipients.

Growth Factors

• Increasing Research and Development (R&D)

R&D in pharmaceutical excipients has increased in past few years. R&D is crucial in pharmaceutical excipients to enhance the production process and product quality, more research, and development is being done in pharmaceutical formulations using multi-functional excipients. Further, with the development of countries like China and India, R&D is expected to increase in the field of pharmaceutical excipients.

• Increasing chronic diseases

With increasing chronic diseases, the growing generics market leads to an increase in the development of excipient is the major factor driving the market growth. With the advancement of drug development, there is an increase in pharmaceutical excipients.

Restraints

Pharmaceutical Excipients require mandatory inspections by the regulatory authorities of the manufacturing site. further, huge investment in R&D is a key drawback. If a new drug approval fails, the excipient also fails even if it is not related to the excipient. Moreover, A huge amount of time and cost goes into creating an excipient.

Impact of COVID–19 on the Pharmaceutical Excipients Market:

Pharmaceutical Excipients have seen growth during the pandemic not just due to rising demand for treatment of COVID-19 patients worldwide but also to meet the demand for vaccines for COVID-19, in addition to the other medicines and drugs. Drugs like hydroxychloroquine and Remdesivir showed positive results against COVID- 19. They were high in demand during the COVID-19 peaks. Since the World Health Organization (WHO) approved several vaccinations, manufacturing has expanded to its maximum capacity. Causing an increase in the demand for pharmaceutical excipients, worldwide.

Competitive Insights

To name a few market players for the global pharmaceutical excipients market are Ashland Global Holdings, DuPont, BASF SE, Roquette Feres, Evonik Industries AG, Croda International amongst others. The players in the market implement growth strategies such as product launches, mergers, acquisitions, etc. to obtain a competitive advantage over competitors. For instance,

• In August 2019, Croda Expands its High Purity Pharmaceutical Excipients Manufacturing Capability by opening a facility in Mill Hall.
• In January 2019 – Croda International Plc, entered into a global sales and marketing agreement with Genesis Biosciences. Croda's existing line of safe and sustainable cleaning raw materials has been expanded by this new agreement.
• In June 2019, Croda International Plc completes the acquisition of Parfex S.A. ('Parfex'), a fine fragrance business located in Grasse, France, for a total enterprise value of €45 million in June 2021 through its wholly-owned subsidiary Iberchem.
• In May 2019, Aceto has acquired a majority share in Finar Limited, a pharmaceutical excipients manufacturer, supplier, and distributor. The purchase will boost Aceto's production base, R&D capabilities, and quality expertise for excipients.
• In 2019, Evonik has announced the opening of a new biomaterials plant in Birmingham, Alabama. It is a multi-functional facility with over 2,800 square meters structure. The facility has been successfully inspected by the US and EU health authorities.
• In June 2019, Roquette opens its pharma online marketplace, which is powered by Knowde. Roquette's flagship pharmaceutical and biopharmaceutical offering will be available in smaller amounts through the e-commerce site.

Segmentation:

By excipient type

• Polymers
• Alcohols
• Sugars
• Minerals
• Others

By formulation type

• Oral
• Topical
• Parenteral
• Others

By functionality

• Coating Agents
• Flavoring Agents & Sweeteners
• Lubricants & Glidants
• Colorants
• Emulsifying Agents
• Buffering Agents
• Others

By Distribution Channel

• Online
• Offline

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• Australia
• Japan
• South Korea
• India
• Thailand
• Taiwan
• Indonesia
• Others